Protocol Ledger

NCT06901830 · Phase II · COMPLETED

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery

Interventional Phase II clinical trial protocol NCT06901830 sponsored by Shanghai Haiyan Pharmaceutical Technology Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-23 Enrollment: 150 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06901830
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06901830
Protocol FieldVerified Registry Value
NCT IdentifierNCT06901830
Consolidated Lead SponsorShanghai Haiyan Pharmaceutical Technology Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment150 participants (ACTUAL)
Registered Start Date2025-05-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06901830
Hospital Research SiteLocationSite Profile
The Third Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Sichuan Provincial People's HospitalChengdu, ChinaOpen Hospital Dossier ->
Dongguan People's HospitalDongguan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI